相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone Signaling
Jing Liu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Managing dyslipidaemia in type 2 diabetes mellitus
Auryan Szalat et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations
Cecilia C. Low Wang et al.
CIRCULATION (2016)
SGLT2 Inhibitors: Benefit/Risk Balance
Andre J. Scheen
CURRENT DIABETES REPORTS (2016)
Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
Changting Xiao et al.
DIABETES (2016)
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
John P. H. Wilding et al.
DIABETES CARE (2016)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2016 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2016)
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes A Meta-analysis
Suetonia C. Palmer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
Xiaohong Yang et al.
JOURNAL OF LIPID RESEARCH (2016)
2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures
Joseph P. Drozda et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial
Stephen J. Nicholls et al.
AMERICAN HEART JOURNAL (2015)
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia A Systematic Review and Meta-analysis
Eliano Pio Navarese et al.
ANNALS OF INTERNAL MEDICINE (2015)
Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
Norm Rosenthal et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014 (2015)
Dietary fatty acids, dietary patterns, and lipoprotein metabolism
Benoit Lamarche et al.
CURRENT OPINION IN LIPIDOLOGY (2015)
Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism
Changting Xiao et al.
DIABETES (2015)
Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
Stephan Matthaei et al.
DIABETES CARE (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Role for Combination Therapy in Diabetic Dyslipidemia
Haider J. Warraich et al.
CURRENT CARDIOLOGY REPORTS (2015)
Prospective association of fatty acids in the de novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study
Wenjie Ma et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2015)
Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
Kira B. Harris et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2015)
Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol-Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus
Maria J. Gutierrez et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
Rajendrakumar H. Jani et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2014)
Prevalence and Incidence Trends for Diagnosed Diabetes Among Adults Aged 20 to 79 Years, United States, 1980-2012
Linda S. Geiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
Eun Yeong Choe et al.
DIABETES & METABOLISM JOURNAL (2014)
Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids
Marius R. Robciuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Hanford Yau et al.
CURRENT DIABETES REPORTS (2013)
Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol
Vineeta Sharma et al.
CURRENT OPINION IN LIPIDOLOGY (2013)
Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
The not-so-simple HDL story Is it time to revise the HDL cholesterol hypothesis?
Daniel J. Rader et al.
NATURE MEDICINE (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Electronegative low-density lipoprotein: Origin and impact on health and disease
Ana Paula Queiroz Mello et al.
ATHEROSCLEROSIS (2011)
Effect of Intensive Glycemic Lowering on Health-Related Quality of Life in Type 2 Diabetes ACCORD trial
Roger T. Anderson et al.
DIABETES CARE (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
William C. Cushman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Russell Scott et al.
DIABETES CARE (2009)
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
Martin Adiels et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Intestinal lipoprotein overproduction in insulin-resistant states
Khosrow Adeli et al.
CURRENT OPINION IN LIPIDOLOGY (2008)
Clinical trials with thiazolidinediones in subjects with Type 2 diabetes - is pioglitazone any different from rosiglitazone?
Sheila A. Doggrell
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
LANCET (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Rinnonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply
Lars Ryden et al.
EUROPEAN HEART JOURNAL (2007)
Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
John B. Buse et al.
DIABETES CARE (2007)
Diabetic dyslipidemia
Tina J. Chahil et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2006)
Metabolic syndrome: Focus on dyslipidemia
Henry N. Ginsberg et al.
OBESITY (2006)
Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia
HN Ginsberg
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Low-density lipoprotein size and cardiovascular risk assessment
M Rizzo et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2006)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia
M Adiels et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
New insights into the regulation of HDL metabolism and reverse cholesterol transport
GF Lewis et al.
CIRCULATION RESEARCH (2005)
Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I
JM Timmins et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus
K Nagashima et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids - I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles
YL Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity
JS Cohn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Gender difference in the impact of type 2 diabetes on coronary heart disease risk
A Juutilainen et al.
DIABETES CARE (2004)
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
E Chiquette et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus:: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins
SE Borggreve et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2003)
The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells
U Dressel et al.
MOLECULAR ENDOCRINOLOGY (2003)
Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet
SS Deeb et al.
JOURNAL OF LIPID RESEARCH (2003)
Cardiovascular disease in type 2 diabetes mellitus - Current management guidelines
AD Mooradian
ARCHIVES OF INTERNAL MEDICINE (2003)
Metabolic origins and clinical significance of LDL heterogeneity
KK Berneis et al.
JOURNAL OF LIPID RESEARCH (2002)
Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance -: Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction
M Haidari et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidemia in diabetes
C Phillips et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Microsomal triglyceride transfer protein: does insulin resistance play a role in the regulation of chylomicron assembly?
C Phillips et al.
ATHEROSCLEROSIS (2002)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis
GH Tomkin et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2001)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study
Z Schlesinger et al.
CIRCULATION (2000)
分享论文
